Aclara to Present at Needham Third Annual Biotechnology Conference
June 10 2004 - 8:11PM
PR Newswire (US)
Aclara to Present at Needham Third Annual Biotechnology Conference
MOUNTAIN VIEW, Calif., June 10 /PRNewswire-FirstCall/ -- ACLARA
BioSciences (NASDAQ:ACLA) announced today that Thomas G. Klopack,
ACLARA's chief executive officer will present at the Needham Third
Annual Biotechnology Conference on Thursday, June 17, 2004 at 8:30
a.m. EDT at the Palace Hotel in New York. About ACLARA Founded in
1995, ACLARA is a biotechnology company working to provide
physicians and researchers products and services to make
personalized medicine a reality through its protein-based assay
technology -- the eTag(TM) System. ACLARA is dedicated to unlocking
the power of pathway biology to accelerate the development of
next-generation targeted therapeutics, recognizing the most
appropriate patients for approved therapies and identifying the
highly-specific, protein-based biomarkers that will enable
physicians to create truly personalized treatment regimens for
patients suffering from cancer and other life-threatening
disorders. ACLARA is commercializing its proprietary eTag System to
enhance and accelerate drug discovery research and the preclinical
and clinical development of targeted therapeutics. ACLARA's
technology may also enable the development of highly-specific,
protein-based diagnostics capable of providing physicians with a
powerful tool for creating personalized treatment regimens for
patients suffering from serious and difficult-to-treat cancers. For
more information on ACLARA please visit the Company's web site at
http://www.aclara.com/. Forward-Looking Statements All statements
in this news release that are not historical are forward-looking
statements within the meaning of the Securities Exchange Act of
1934 as amended. Such forward-looking statements are subject to
factors that could cause actual results to differ materially for
ACLARA from those projected. Those factors include risks and
uncertainties relating to the performance of our products,
anticipated progress in commercialization of our eTag(TM) assay
system; the potential for use of our eTag assays in clinical
development programs; the potential for use of our eTag assays as
diagnostic tests; our ability to successfully conduct clinical
studies and the results obtained from those studies; our ability to
establish reliable, high-volume operations at commercially
reasonable costs; expected reliance on a few customers for the
majority of our revenues; actual market acceptance of our products
and adoption of our technological approach and products by
pharmaceutical and biotechnology companies; our estimate of the
size of our markets; our estimates of the levels of demand for our
products; our ability to develop organizational capabilities
suitable for the further development and commercialization of our
eTag assays; the ultimate validity and enforceability of our patent
applications and patents; the possible infringement of the
intellectual property of others; technological approaches of ACLARA
and our competitors; our pending merger with ViroLogic, Inc.,
including the risk that the closing conditions or the merger may
not be satisfied and the merger may not be completed, and costs
related to the proposed merger; and other risk factors identified
in our Form 10-Q for the quarter ended March 31, 2004 as filed with
the Securities and Exchange Commission. NOTE: ACLARA BioSciences is
a registered trademark, and eTag and the ACLARA logo are trademarks
of ACLARA BioSciences, Inc. DATASOURCE: ACLARA BioSciences CONTACT:
Alfred Merriweather, VP, Finance and CFO of ACLARA BioSciences,
+1-650-210-1200, or Web site: http://www.aclara.com/
Copyright
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Aug 2023 to Aug 2024